Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia
2012-002052-17Phase 3Completed
- Sponsor
- Medical University of Graz
- Start
- Sep 2012
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of imiquimod in vulvar intraepithelial neoplasia (VIN) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Complete clinical response at 6 months. Started Sep 2012; status: completed.
02
Drugs
imiquimod
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on 2012-002052-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002052-17.